The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.
Eligibility
Sex
MALE
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria:
* Men aged 18 to 60 years with a clinical diagnosis of androgenetic alopecia ;
* Participants who use an acceptable contraceptive method, or who declare that their partner uses an acceptable contraceptive method, according to the protocol, and who agree to use it throughout the study period.
Exclusion Criteria:
* History of allergic reactions to any of the active ingredients or to any of the ingredients of teh formulation;
* Participants with a history of alcohol, substance, or illicit drug abuse disorder in the last 2 years;
* Participants with conditions that may affect hair growth or with underlying conditions that cause hair loss, such as a diagnosis of alopecia areata, fibrosing or cicatricial alopecia, or telogen effluvium, the latter being present at the time of screening;
* Participants with concomitant inflammation or other dermatological conditions of the scalp, such as moderate or severe psoriasis or seborrheic dermatitis, and/or active infection and/or keloid formation in the area of alopecia;
Primary outcome measure(s)
Variation in hair density assessed by phototrichogram. — Change from baseline after 24 weeks of treatment.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.